Cephalon’s Treanda Approved For Indolent Non-Hodgkin’s Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says convenient dosing schedule is a plus for the drug, though it will be combined – not competing – with other NHL chemotherapy agents.
You may also be interested in...
CTI Bags Cash, Turns Its Back On Zevalin
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
CTI Bags Cash, Turns Its Back On Zevalin
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
Niche, Lackluster: Two Words That Sum Up 2008 NME Launches
The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior